Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Project Information

ImmuneHunter

Grant agreement ID: 791323

DOI

10.3030/791323

Project closed

EC signature date 31 October 2017

Start date 1 November 2017

End date 30 April 2018

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

PROTOBIOS OU
Estonia

Periodic Reporting for period 1 - ImmuneHunter (Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously)

Reporting period: 2017-11-01 to 2018-04-30

Summary of the context and overall objectives of the project

ImmuneHunter aims to develop a cutting- edge solution - a state-of-the-art clinical analysis tools paired with ICT platform, to help change medicine into a data-driven competence. Widening our immunologic knowledge of diseases would allow to diagnose and intervene early and offer the patients yet the unknown therapeutic possibilities.
Chronic diseases (cancer, heart and mind diseases) are the leading cause of illness and death. Disease rate from these conditions is accelerating globally across all socioeconomic classes. By 2020 their contribution is expected to rise to 73% of all deaths (of which nearly half as premature) and 60% of the global burden of disease. To radically reduce the related healthcare spending and contribute to healthy ageing, it is important to diagnose chronic diseases as early and accurately as possible by analyzing biomarkers

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The ImmuneHunter project aimed at enhancing the company’s current analytical and data handling and management capabilities for fast processing of each clinical sample according to the customized market needs. For that, our aim was to first, specify end-user requirements and use this information for required technical adjustments. As an outcome we could successfully target the other objectives that were to elaborate the business strategy and in conjunction with this also to assess the linked IP matters, identify the strategic partners and amend the business plan accordingly.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The key outcome was the development of a strategy that allows highly accurate and informative biomarker measurings for making better clinical decisions early in the disease process. The development of disease biomarker panels will allow patient stratification for the most optimal therapy, more detailed understanding of the progression of disease and fast diagnostic assessment on the response to treatment. Also avoid invasive or expensive procedures for diagnostic assessments. By completing ImmuneHunter we have made a small step closer to our ultimate goal what is to improve public health and health aging by supporting fast, low-cost and accurate health-audits.

SME1 Project